Showing results (171-180 of 280) with videos related to

Sort By:
Pageof 28
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based reviewDenise M Oliansky, Joseph H Antin, John M Bennett, et al.
Leukemia & Lymphoma|December 27, 2024
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignanciesJeffrey Baron, Daniel Appiah, Mark G Faber, et al.
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
JNCI Cancer Spectrum|December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experienceJoaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Leukemia Research|September 10, 2013
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of ageCarlos E Vigil, Wei Tan, George Deeb, et al.
Leukemia Research|May 23, 2013
Myelodysplastic syndromes and autoimmune diseases--case series and review of literatureOmar Al Ustwani, Laurie A Ford, Sheila J N Sait, et al.
Oncotarget|February 18, 2016
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapyPragya Srivastava, Benjamin E Paluch, Junko Matsuzaki, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Pageof 28